Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GeNeuro SA
- Target Recruit Count
- 203
- Registration Number
- NCT05497089
- Locations
- 🇨ðŸ‡
REHAB Clinic for Neurorehabilitation and Paraplegiology, Basel, Switzerland
🇮🇹Hospital of Vipiteno, Vipiteno, Italy
🇮🇹Clinica Metabolica dell'Università di Modena e Reggio Emilia, Modena, Italy
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
Phase 2
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: GNbAC1 Monoclonal Antibody
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro SA
- Target Recruit Count
- 220
- Registration Number
- NCT03239860
- Locations
- 🇺🇦
Hospital, Kharkiv, Ukraine
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
Phase 2
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: GNbAC1Drug: Placebo
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GeNeuro SA
- Target Recruit Count
- 270
- Registration Number
- NCT02782858
© Copyright 2025. All Rights Reserved by MedPath